Skip to main content
. 2020 Jun 26;39(6):1717–1723. doi: 10.1007/s00345-020-03318-5

Table 1.

Patients’ and stones’ baseline characteristics

Total: 122
Sex, N° (%)
 Male 74 (60.6)
 Female 48 (39.4)
Mean age (± SD), years 55.2 (± 14.5)
BMI, N° (%)
 < 18.5 5 (4.1)
 18.5–24.9 60 (49.2)
 25–29.9 47 (38.5)
 ≥ 30 10 (8.2)
Comorbidities, N° (%)
 Diabetes 17 (13.9)
 Hypertension 32 (26.2)
 Cardiovascular disease 12 (9.8)
 Chronic kidney disease 3 (2.5)
 Inflammatory bowel disease 5 (4.1)
 Hyperparathyroidism 3 (2.5)
 Haemorrhagic diathesis 2 (1.6)
 Recurrent urinary tract infections 22 (18.3)
Drugs, N° (%)
 Anticoagulants 4 (3.3)
 Antiplatelets 16 (13.1)
American Society of Anesthesiologists score, N° (%)
 1 22 (18)
 2 79 (64,8)
 3 21 (17.2)
Charlson Comorbidity Index, N° (%)
 0 88 (72.1)
 1 19 (15.6)
 2 8 (6.5)
 3 3 (2.5)
 4 3 (2.5)
 5 1 (0.8)
Urinary tract abnormalities, N° (%) 6 (4,9)
 Renal malrotation 2 (1.6)
 Horseshoe kidney 1 (0.8)
 Ectopic kidney 1 (0.8)
 Duplex ureter 2 (1.6)
Single kidney, N° (%) 3 (2.5)
Skeletal abnormalities, N° (%) 2 (1.6)
Previous homolateral stone treatment, N° (%) 61 (50)
Stone number, N° (%)
 Single 48 (39.3)
 Multiple 74 (60.7)
Median total stone volume (IQR), cm3 1.92 (1–3.1)
Median mean stone density (IQR), HU 850 (550–998)
Stone location, N° (%)
 Lower calyx 15 (12.3)
 Middle calyx 6 (4.9)
 Renal pelvis 24 (19.6)
 Upper calyx 4 (3.3)
 Multiple locations 73 (59.9)
Pre-operative positive urine culture, N° (%) 19 (15.6)
Stone composition, N° (%)
 Calcium Oxalate Monohydrate 38 (31.1)
 Calcium Oxalate Dihydrate 26 (21.3)
 Uric acid 25 (20.5)
 Calcium Carbonate + Calcium Oxalate 10 (8.2)
 Calcium Carbonate 7 (5.7)
 Calcium Oxalate Mono + Dihydrate 5 (4.1)
 Calcium Phosphate 4 (3.3)
 Cystine 4 (3.3)
 Struvite 3 (2.5)